These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 11399831)
1. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT? Roth WK; Seifried E Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831 [No Abstract] [Full Text] [Related]
2. Kill and cure. The hope and reality of virus inactivation. Prowse C Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491 [No Abstract] [Full Text] [Related]
3. [Viral safety measures of plasma for transfusion and applicability in Spain]. Pereira A Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912 [No Abstract] [Full Text] [Related]
4. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Wagner SJ; Friedman LI; Dodd RY Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274 [No Abstract] [Full Text] [Related]
5. Genomic screening for blood-borne viruses in transfusion settings. Lee HH; Allain JP Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433 [No Abstract] [Full Text] [Related]
6. Is there a limit to the normality of blood products? Degos L Hematol J; 2000; 1(5):291. PubMed ID: 11920204 [No Abstract] [Full Text] [Related]
7. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Weusten JJ; van Drimmelen HA; Lelie PN Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161 [TBL] [Abstract][Full Text] [Related]
8. The role of leukodepletion in the control of transfusion-transmitted disease. Goldman M; Delage G Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040 [No Abstract] [Full Text] [Related]
13. Reduction of virus load in blood donations by screening methods. Kühnl P; Seidl S; Böhm BO Curr Stud Hematol Blood Transfus; 1989; (56):9-22. PubMed ID: 2642787 [No Abstract] [Full Text] [Related]
14. Monetary blood donation incentives and the risk of transfusion-transmitted infection. Eastlund T Transfusion; 1998 Sep; 38(9):874-82. PubMed ID: 9738629 [No Abstract] [Full Text] [Related]
15. Strategies for reducing the exposure to donor blood. Murphy M Clin Med (Lond); 2005; 5(4):337-40. PubMed ID: 16138487 [No Abstract] [Full Text] [Related]
16. Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections. Tani Y; Aso H; Matsukura H; Tadokoro K; Tamori A; Nishiguchi S; Yoshizawa H; Shibata H; Vox Sang; 2012 May; 102(4):285-93. PubMed ID: 22082342 [TBL] [Abstract][Full Text] [Related]
17. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009. Al Shaer L; AbdulRahman M; John TJ; AlHashimi A Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239 [TBL] [Abstract][Full Text] [Related]
18. Safety of the blood supply. Sloand EM; Pitt E; Klein HG JAMA; 1995 Nov; 274(17):1368-73. PubMed ID: 7563562 [No Abstract] [Full Text] [Related]
19. [Current tactics in reducing hazards of virus infection transmission during blood transfusion]. Golosova TV Gematol Transfuziol; 1992 Mar; 37(3):35-7. PubMed ID: 1516800 [No Abstract] [Full Text] [Related]
20. Inactivation of viruses in blood and plasma products. Suomela H Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658 [No Abstract] [Full Text] [Related] [Next] [New Search]